Bo Dai

Shanghai Medical College of Fudan University — China

Medicine · Health Sciences

38h-index4.9kcitations205works12.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(57), Renal cell carcinoma treatment(43), Bladder and Urothelial Cancer Treatments(37), Prostate Cancer Diagnosis and Treatment(31), Cancer Immunotherapy and Biomarkers(25)

Publications205 total

Correction: Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide
Oncogene·2026Open Access
From non-clinically significant to clinically significant prostate cancer: identifying predictors of discrepancy from biopsy to radical prostatectomy
Asian Journal of Andrology·2025Open Access
Early clinical experience with the Carina robotic platform in urologic surgery
BJUI Compass·2025· 2 citedOpen Access
Effects of a deep learning network on imaging quality of low- <i>b</i> -value diffusion–weighted imaging and lesion detection in prostate cancer.
Journal of Clinical Oncology·2025
Deep learning network enhances imaging quality of low-b-value diffusion–weighted imaging and improves lesion detection in prostate cancer
BMC Cancer·2025· 4 citedOpen Access
A propensity score-matched analysis on biopsy methods: enhanced detection rates of prostate cancer with combined cognitive fusion-targeted biopsy
Asian Journal of Andrology·2025Open Access
Gut microbiota and osteonecrosis: A Mendelian randomization study
Medicine·2025· 2 citedOpen Access
Mitoxantrone‐Encapsulated ZIF‐8 Enhances Chemo‐Immunotherapy via Amplified Immunogenic Cell Death
Advanced Science·2025· 16 citedOpen Access
AMPK: An energy sensor for non-small cell lung cancer progression and treatment
Pharmacological Research·2025· 7 citedOpen Access
Policy pathways through FinTech and green finance for low-carbon energy transition in BRICS nations
Energy Strategy Reviews·2025· 21 citedOpen Access
IKBKE regulates renal cell carcinoma progression and sunitinib resistance through the RRM2-AKT pathway
International Journal of Biological Sciences·2024· 2 citedOpen Access
CACA guidelines for holistic integrative management of prostate cancer
Holistic Integrative Oncology·2024· 17 citedOpen Access
971P Chemotherapy combined with lenvatinib and PD-1 may be a potential better alternative optionfor advanced unresectable intrahepatic cholangiocarcinoma: A retrospective real-world study
Annals of Oncology·2024
Advantage of whole-mount histopathology in prostate cancer: current applications and future prospects
BMC Cancer·2024· 5 citedOpen Access
Accurate categorization and rapid pathological diagnosis correction with Micro-Raman technique in human lung adenocarcinoma infiltration level
Translational Lung Cancer Research·2024Open Access
Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
Biomedicine & Pharmacotherapy·2024· 130 citedOpen Access
Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide
Oncogene·2024· 13 cited
A deep learning model, NAFNet, predicts adverse pathology and recurrence in prostate cancer using MRIs
npj Precision Oncology·2023· 16 citedOpen Access
Identification and validation of molecular subtypes’ characteristics in bladder urothelial carcinoma based on autophagy-dependent ferroptosis
Heliyon·2023· 6 citedOpen Access
1775P A newly-developed deep-learning algorithm: NAFNet outperforms ResNet50 for predicting adverse pathology events and biochemical recurrence time using MRI from prostate cancer patients
Annals of Oncology·2023Open Access
page 1 of 11Next →

Frequent Co-authors

Yao Zhu(27), Yijun Shen(15), Dingwei Ye(15), Yu Zhu(13), Jiejie Xu(12), Guohai Shi(11), Le Xu(9), Quan Zhou(9), Jianming Guo(9), Fangning Wan(9), Han Zeng(8), Kun Chang(8), Qi Bai(8), Yu Xia(8), Li Liu(8), Hailiang Zhang(8), Dingwei Ye(8), Yiping Zhu(7), Xu-Dong Yao(7), Shi-Lin Zhang(7)